PMID- 36265575
OWN - NLM
STAT- MEDLINE
DCOM- 20221206
LR  - 20221228
IS  - 1096-0007 (Electronic)
IS  - 0014-4835 (Linking)
VI  - 225
DP  - 2022 Dec
TI  - Resveratrol increases tear production and ocular pain after corneal abrasion in 
      male, but not female, rats using a photorefractive keratectomy model.
PG  - 109281
LID - S0014-4835(22)00362-1 [pii]
LID - 10.1016/j.exer.2022.109281 [doi]
AB  - Photorefractive keratectomy (PRK) is an alternative to LASIK and can cause 
      intense acute pain that is often not relieved by standard treatments. To assess 
      potential therapeutics for this type of acute pain, appropriate preclinical 
      models are needed. We describe a preclinical corneal abrasion rat model that 
      simulates the initial stages of PRK surgery and demonstrates similar pain and 
      tear dysfunction as seen clinically. We used both behavioral and homeostatic 
      assays to determine the therapeutic potential of resveratrol on pain and tear 
      production. Studies were conducted in male and female Sprague-Dawley rats. 
      Heptanol was applied to one eye and the superficial corneal epithelium was 
      removed, mimicking the abrasion used in PRK. Spontaneous pain was assessed with 
      orbital tightening (OT) scores for 7 days. Topical resveratrol increased OT 
      scores sex-specifically in abraded males, but not females, at 72 h and 1 week 
      after abrasion. Resveratrol increased tear production in abraded males, with no 
      effect in abraded females. There was no correlation between OT score at 1 week 
      and tear production measurements, demonstrating no relationship between 
      spontaneous ocular pain and tear dysfunction in this model. These findings 
      demonstrate the usefulness of our corneal abrasion preclinical PRK model for the 
      assessment of ocular pain therapeutics and indicate that topical resveratrol may 
      not be useful for managing PRK-induced pain.
CI  - Copyright (c) 2022 Elsevier Ltd. All rights reserved.
FAU - Hegarty, Deborah M
AU  - Hegarty DM
AD  - Department of Chemical Physiology & Biochemistry, Oregon Health & Science 
      University, Portland, OR, 97239, USA.
FAU - Carroll, James R
AU  - Carroll JR
AD  - Department of Chemical Physiology & Biochemistry, Oregon Health & Science 
      University, Portland, OR, 97239, USA.
FAU - Nguyen, Dennis
AU  - Nguyen D
AD  - Department of Chemical Physiology & Biochemistry, Oregon Health & Science 
      University, Portland, OR, 97239, USA.
FAU - Halls, Victoria S
AU  - Halls VS
AD  - Medicinal Chemistry Core, Oregon Health & Science University, Portland, OR, 
      97239, USA.
FAU - Robbins, Dennis I
AU  - Robbins DI
AD  - Ted's Brain Science, Inc., Dallas, TX, 75252, USA.
FAU - Price, Theodore J
AU  - Price TJ
AD  - Ted's Brain Science, Inc., Dallas, TX, 75252, USA; School of Behavioral and Brain 
      Sciences, Department of Neuroscience, Center for Advanced Pain Studies, 
      University of Texas at Dallas, Richardson, TX, 75080, USA.
FAU - Dussor, Gregory
AU  - Dussor G
AD  - Ted's Brain Science, Inc., Dallas, TX, 75252, USA; School of Behavioral and Brain 
      Sciences, Department of Neuroscience, Center for Advanced Pain Studies, 
      University of Texas at Dallas, Richardson, TX, 75080, USA.
FAU - Aicher, Sue A
AU  - Aicher SA
AD  - Department of Chemical Physiology & Biochemistry, Oregon Health & Science 
      University, Portland, OR, 97239, USA. Electronic address: aichers@ohsu.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20221018
PL  - England
TA  - Exp Eye Res
JT  - Experimental eye research
JID - 0370707
RN  - Q369O8926L (Resveratrol)
SB  - IM
MH  - Male
MH  - Rats
MH  - Animals
MH  - *Photorefractive Keratectomy/adverse effects
MH  - Resveratrol
MH  - Lasers, Excimer
MH  - *Acute Pain/surgery
MH  - *Myopia
MH  - Rats, Sprague-Dawley
MH  - *Corneal Injuries/drug therapy/surgery
MH  - *Epithelium, Corneal
MH  - Cornea
OTO - NOTNLM
OT  - Cornea
OT  - Orbital tightening
OT  - Sex differences
OT  - Tears
COIS- Declaration of competing interest D.M. Hegarty, None; J.R. Carroll, None; D. 
      Nguyen, None; V.S. Halls, None; D.I. Robbins, Ted's Brain Science (O); T.J. 
      Price, Ted's Brain Science (O); G. Dussor, Ted's Brain Science (O); S.A. Aicher, 
      None. Ted's Brain Science is a company developing resveratrol-based therapeutics 
      for pain.
EDAT- 2022/10/21 06:00
MHDA- 2022/12/07 06:00
CRDT- 2022/10/20 19:32
PHST- 2022/07/11 00:00 [received]
PHST- 2022/09/23 00:00 [revised]
PHST- 2022/10/13 00:00 [accepted]
PHST- 2022/10/21 06:00 [pubmed]
PHST- 2022/12/07 06:00 [medline]
PHST- 2022/10/20 19:32 [entrez]
AID - S0014-4835(22)00362-1 [pii]
AID - 10.1016/j.exer.2022.109281 [doi]
PST - ppublish
SO  - Exp Eye Res. 2022 Dec;225:109281. doi: 10.1016/j.exer.2022.109281. Epub 2022 Oct 
      18.